Skip to content

Enliven Therapeutics

US · ELVN #2416 by market cap Listed 1970
46.53 +0.12 +0.26%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

✦ Quant Ownership Signal how this is computed

Accumulating
  • The number of reporting institutions increased by 9 in the most recent period (2026/Q3).
  • Total institutional ownership rose 5.4 percentage points.

Ownership vs. money flow

Diverging

Institutions added shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two are pointing in different directions.

Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.

Institutional ownership

Held by institutions
118.03% +5.42pp
Institutions
260 +9
As of
2026/Q3 vs. prior period

Holder types

Mutual Fund67.39%
Hedge Fund32.50%
VC/PE Fund14.08%
Individual/Insider2.69%
Sovereign Wealth Fund1.88%
Public Company1.23%
Insurance Company0.45%
Government Pension Fund0.32%
Private Company0.17%

Top holders as of 2026-09-30

FMR 14.71% · 10.83M sh
OrbiMed Advisors LLC 9.21% · 6.78M sh
Polar Capital Holdings Plc 8.74% · 6.43M sh
BlackRock 7.07% · 5.21M sh
Vestal Point Capital, LP 5.44% · 4.00M sh
Commodore Capital LP 4.45% · 3.28M sh
T. Rowe Price Group, Inc. 4.35% · 3.20M sh
Vanguard Capital Management, LLC 3.93% · 2.89M sh
Citadel Advisors LLC 2.81% · 2.07M sh
Fairmount Funds Management LLC 2.52% · 1.86M sh

Bar length is relative to the largest holder shown here, not to 100% of the company.

Insiders

50 filings tracked · 15 buys · 35 sells

NameRoleStake
Joseph Lyssikatos Co-Founder & Research Fellow 1.01%
Samuel Kintz Co-Founder & Head of Pipeline 0.89%
Anish Patel Co-Founder & COO 0.29%
Richard Heyman Former Independent Chairperson 0.23%
Jacob Bauer Independent Director 0.12%
Lori Kunkel Independent Director 0.07%
Helen Collins Chief Medical Officer 0.03%
Rahul Ballal Director 0.03%
Benjamin Hohl CFO & Head of Corporate Development 0.02%
OrbiMed Advisors LLC -- --

Insider transactions most recent Form 4 filings

DateNameRoleTypeSharesPrice
2026-10-29 Lori Kunkel Independent Director Derivative Exercise and Retained +11,041 $1.12–18.30
2026-10-18 Helen Collins Chief Medical Officer Derivative Exercise and Sale -5,000 $2.48–38.47
2026-10-18 Benjamin Hohl CFO & Head of Corporate Development Derivative Exercise and Sale -6,018 $14.85–38.48
2026-10-13 Kristine Ball Director Other Derivative Acquisition +23,394 $39.28
2026-09-30 Scott Garland Director Derivative Exercise and Sale -13,000 $15.47–46.67
2026-09-16 Helen Collins Chief Medical Officer Derivative Exercise and Sale -5,000 $2.48–51.48
2026-09-16 Benjamin Hohl CFO & Head of Corporate Development Open Market Disposition -2,036 $50.72–51.49
2026-09-16 Benjamin Hohl CFO & Head of Corporate Development Derivative Exercise and Sale -3,982 $14.85–50.72
2026-09-03 Richard Heyman Former Independent Chairperson Intent to Sell (Form 144) -38,000 $59.29
2026-08-16 Helen Collins Chief Medical Officer Derivative Exercise and Sale -5,000 $2.48–59.35
2026-08-16 Benjamin Hohl CFO & Head of Corporate Development Automatic Disposition -6,018 $58.35–59.35
2026-08-03 Mika Derynck Independent Director Derivative Exercise and Sale -158,795 $2.48–60.21
2026-07-16 Helen Collins Chief Medical Officer Derivative Exercise and Sale -5,000 $2.48–53.92
2026-07-16 Benjamin Hohl CFO & Head of Corporate Development Automatic Disposition -4,946 $52.32–53.87
2026-07-16 Benjamin Hohl CFO & Head of Corporate Development Derivative Exercise and Sale -1,072 $2.48–52.32
2026-07-05 Lori Kunkel Independent Director Automatic Disposition -10,000 $49.98–50.84
2026-06-21 OrbiMed Advisors LLC -- Private Disposition -48,253 $45.00
2026-06-21 OrbiMed Advisors LLC -- Open Market Disposition -811,870 $45.38
2026-06-16 Helen Collins Chief Medical Officer Derivative Exercise and Sale -5,000 $2.48–44.74
2026-06-16 Benjamin Hohl CFO & Head of Corporate Development Derivative Exercise and Sale -6,018 $2.48–44.75

Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.

Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.

Enliven Therapeutics discussion 0 comments

Add a comment